Three ways to engage.
This page is for investors, partners, and press. If you are looking for one of our products, the cards will take you there directly.
Tell us who you are. We'll know how to help.
Investors
Neural Omega is currently pre-commercial, with public funding from ENISA and NextGenerationEU under the Plan de Recuperación. Roadmap toward Maia Clinical launch (June 2026) and BioSpain 2026 (September). Formal funding round expected in 2027. We are open to early conversations now.
Direct contact →Partners
We work directly with patient associations representing autoimmune communities, clinical societies (SER, SEMI-GEAS, AEDV and others), and hospitals interested in piloting Maia Clinical. Pharma partnership conversations for Massa begin from BioSpain 2026 onward.
Get in touch →Press
Press kit available on request: founder bio, company background, technical architecture overview, and brand assets. We respond to press enquiries within 48 hours during the week. For embargoed enquiries please flag explicitly.
Request press kit →In Madrid. In Bilbao. On LinkedIn.
BioSpain 2026
The Spanish biotech sector's reference event. If you want a meeting at the booth, request it in advance — the agenda fills up quickly.
Request a meeting →